{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-070285","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.292821+00:00","generated_at":"2026-05-31T08:49:53.224919+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Citius Pharma completes SPAC merger, forms Citius Oncology; holds ~90% of new public company","bullets":["Merger closed Aug 12, 2024; Citius Oncology expected to trade on Nasdaq as CTOR on Aug 13.","Citius Pharma owns approximately 90% of Citius Oncology after the merger.","LYMPHIR (denileukin diftitox) approved by FDA for relapsed/refractory cutaneous T-cell lymphoma.","Citius Pharma made $3.8M capital contribution to Citius Oncology via no-interest promissory note.","Amended shared services and registration rights agreements executed; shares subject to 6-month lock-up."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-070285","json":"https://secwatch.observer/filing/0001213900-24-070285.json","markdown":"https://secwatch.observer/filing/0001213900-24-070285.md","text":"https://secwatch.observer/filing/0001213900-24-070285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024070285/0001213900-24-070285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024070285/ea0211482-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:49:53.224919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}